Status:
COMPLETED
The Association of MicroRNA21-155 Levels With Acute Side Effects In Patients With Stage III NSCLC With Definitive CRT
Lead Sponsor:
Ankara University
Conditions:
Non-small Cell Lung Cancer Stage III
Eligibility:
All Genders
18-85 years
Brief Summary
The present investigation constitutes a prospective cohort study. The objectives encompass the assessment of miRNA expression levels in total exosomes derived from peripheral circulation tissues of st...
Detailed Description
Categorical variables were illustrated using both percentage distributions and numerical counts, while continuous variables were characterized using the mean accompanied by the standard deviation, and...
Eligibility Criteria
Inclusion
- Patient over 18 years old.
- To be between 0-2 according to Eastern Cooperative Oncology Group (ECOG) performance status (PS).
- Patient with pathological diagnosis of NSCLC.
- Stage 3 Patient
- Patient with a definitive chemoradiotherapy (CRT) treatment plan.
Exclusion
- Patient with second primary malignancy.
- History of previous radiotherapy to the thoracic region
- Patient with advanced cardiovascular disease.
- Patient with neurological or physical deficit.
- Patient with autoimmune disease
Key Trial Info
Start Date :
October 5 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 15 2020
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT06015815
Start Date
October 5 2019
End Date
August 15 2020
Last Update
August 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ankara University Medicine School Radiation Oncology
Ankara, Turkey (Türkiye), 06590